Mereo BioPharma Group plc (AIM:MPH)
London · Delayed Price · Currency is GBP · Price in GBX 26.50
-0.50 (-1.85%)
At close: Dec 17, 2020
Mereo BioPharma Group Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -35.71 | -41.88 | -43.25 | -29.47 | -42.22 | 17.23 |
Depreciation & Amortization | 1.18 | 1.15 | 1.09 | 1.06 | 0.89 | 0.87 |
Loss (Gain) From Sale of Assets | - | - | - | - | - | -0.15 |
Stock-Based Compensation | 6.93 | 7.6 | 7.39 | 4.92 | 4.77 | 4.47 |
Other Operating Activities | 1.18 | 5.36 | 2.31 | 3.94 | -9.91 | -27.01 |
Change in Accounts Receivable | - | - | - | - | - | -0.8 |
Change in Accounts Payable | 0.22 | -1.38 | 0.15 | -1.26 | 0.62 | -1.7 |
Change in Other Net Operating Assets | -0.75 | -1.83 | -0.52 | -0.33 | -2.97 | - |
Operating Cash Flow | -26.95 | -30.97 | -32.83 | -21.13 | -48.82 | -7.09 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | -0.02 | - | - | -0.01 | -0.72 |
Sale (Purchase) of Intangibles | - | - | -0.7 | -0.42 | 2 | 0.15 |
Other Investing Activities | - | - | - | - | - | 0 |
Investing Cash Flow | - | -0.02 | -0.7 | -0.42 | 1.99 | -0.57 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | - | - | -3.19 | - | -0.94 |
Net Debt Issued (Repaid) | - | - | - | -3.19 | - | -0.94 |
Issuance of Common Stock | 0.04 | 0.53 | 47 | 11.61 | - | 106.4 |
Other Financing Activities | -0.13 | -0.2 | -0.85 | -0.44 | 0.2 | -0.32 |
Financing Cash Flow | -0.1 | 0.33 | 46.15 | 7.97 | 0.2 | 105.15 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.79 | 1.85 | -0.23 | 2.82 | -12.58 | -1.58 |
Miscellaneous Cash Flow Adjustments | - | - | - | -0 | - | - |
Net Cash Flow | -26.26 | -28.81 | 12.38 | -10.76 | -59.22 | 95.9 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -26.95 | -30.99 | -32.83 | -21.13 | -48.83 | -7.82 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -5390.80% | -6198.20% | - | -211.32% | - | -15.83% |
Free Cash Flow Per Share | -0.17 | -0.19 | -0.22 | -0.16 | -0.41 | -0.07 |
Levered Free Cash Flow | -14.36 | -17.92 | -21.5 | -14.17 | -32.74 | -9.08 |
Unlevered Free Cash Flow | -14.3 | -17.76 | -20.64 | -12.37 | -30.13 | -5.88 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.03 | 0.03 | 0.02 | 0.88 | 0.02 | - |
Cash Income Tax Paid | - | - | - | -1.34 | 1.88 | - |
Change in Working Capital | -0.53 | -3.2 | -0.37 | -1.59 | -2.35 | -2.5 |